| Year | Detail |
| 1952 |
Cadila Laboratories Ltd. established by Mr. Ramanbhai B. Patel. |
| 1995 - 1996 |
Acquired Indo Pharma Pharmaceutical Works Ltd – the group’s first acquisition. |
| 1997 - 1998 |
Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV. |
| 1999 - 2000 |
Entered into JV with Sarabhai for consolidating its position in Animal Healthcare. |
| 2000 - 2001 |
Zydus Research Centre set up at Moraiya and Acquired Recon Healthcare, which boosted Zydus’s strengths in southern markets. |
| 2000 - 2002 |
Acquired German Remedies – the largest M&A in the Indian pharmaceutical sector at the time. |
| 2001 - 2002 |
Acquired Aten and attained the top spot in the cardiovascular segment in India, Acquired USFDA approved API plant, Banyan Chemicals. |
| 2002 - 2003 |
Zydus Pharmaceuticals (USA) Inc. incorporated. |
| 2003 - 2004 |
Acquired Alpharma France (renamed Zydus France) – Zydus’s first international acquisition. |
| 2005 - 2006 |
Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd. |
| 2006 - 2007 |
Acquired Liva Healthcare and entered the dermatology market in India, Acquired Nippon Universal and entered the Japanese market. |
| 2007 - 2008 |
Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda. |
| 2008 - 2009 |
Acquired Laboratorios Combix in Spain, Simayla Pharma in South America, and Etna Biotech in Italy. |
| 2009 - 2010 |
Launched first formulation using nano-technology platform in India – Oxalgin Nanogel. |
| 2010 - 2011 |
Entered into a 50:50 JV with Bayer to set up a new marketing company. Entered into strategic agreement with Abbott for commercializing branded generics in emerging markets. Launched Vaxiflu – S, India’s first H1N1 vaccine. |
| 2011 - 2012 |
Acquired 100% stake in Biochem, one of the top 40 pharma companies in India. Acquired Bremer Pharma GmbH to gain a global footprint in the animal healthcare business. Acquired the assets of US-based Nesher Pharmaceuticals Inc. Received USFDA approval of Baddi manufacturing plant. |
| 2013 |
Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes. |
| 2014 |
Zydus launched world’s first biosimilar of adalimumab. |
| 2016 |
Zydus acquired Zoetis, a global animal health company, Zydus and Takeda entered into partnership to address emerging infection diseases. |
| 2017 |
Zydus Cadila acquired Sentynl Therapeutics Inc., US-based specialty company. Zydus launched India’s first Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4. |
| 2018 |
Cadila Healthcare acquired 51% stake in Windlas Healthcare. Zydus partnered with Medicure to launch its NDA product, ZYPITAMAG. |
| 2019 |
Zydus Wellness Ltd. completed the acquisition of Heinz India Private Limited. |
| 2020 |
Cadila Healthcare Ltd. received USFDA approval to initiate clinical trials of desidustat in chemotherapy induced anemia (CIA). |
| 2021 |
Zydus Cadila’s ZyCoV-D vaccine, the first plasmid DNA vaccine to be approved for human use in the world, was granted Emergency Use Authorization in India. |
| 2022 |
Cadila Healthcare Limited rebranded to Zydus Lifesciences Limited. |